Developer docs
API playgroundTry for free, no card

Search company profiles

INanoBio

Full company profile

uuid000378b

Namestring
INanoBio
Legal namestring
INanoBio Inc.
Websiteurl
inanobio.com
Company typeenum
Private
Founded yearint
2009
Descriptiontext

INanoBio Inc. is a private, pre-commercial biotechnology company developing nano-biotechnology platforms for early-stage disease diagnostics. Founded in 2009 and headquartered in Menlo Park, California with an additional office in Scottsdale, Arizona, the company is led by founder and CEO Bharath Takulapalli. Its stated mission is to develop high-accuracy early-stage disease diagnostics by combining CMOS semiconductor nanotechnology, systems biology, and machine learning to detect disease-specific molecular biomarkers at prodromal or pre-symptomatic stages, with the long-term vision of preemptive medicine.

The company's core technology is a CMOS semiconductor-based 3D Nanopore Transistor device intended to sequence whole human genomes with claimed high accuracy at approximately one-tenth the current cost and over 100 times the speed of protein nanopore-based sequencers. This underpins three interconnected product offerings: (1) a 3D Nanopore-Transistor Genome Sequencer for population-scale sequencing and precision medicine; (2) a Cancer Blood Test Platform that detects cancer-related biomarkers in blood with ultra-high sensitivity, intended to obviate biopsy and enable early diagnosis where stage 1 five-year survival is close to 90% versus less than 25% at stage 4; and (3) the FENT (Fast Electrochemical Nanopore Transistor) Prototype, announced in 2021 as a milestone toward ultra-fast DNA sequencing. Additional R&D streams include an Epigenetic Sequencer funded under the DARPA ECHO Program and an automated high-throughput proteomic assay system funded by an NIH SBIR grant.

INanoBio is pre-revenue and not yet commercially launched. Its go-to-market motion targets enterprise healthcare systems, diagnostic laboratories, and biomedical research institutions through direct field sales and conference-driven visibility (PMWC, MSTC, IEEE VLSI TSA). Anticipated revenue streams are hardware sales of sequencer devices and one-time licensing of cancer diagnostic blood tests, though no pricing has been publicly disclosed. To date, capital has come primarily from non-dilutive sources: a $5.4M DARPA award (2019) and a $0.7M NIH SBIR grant (2019), alongside a 2018 Series Seed round (amount undisclosed in primary sources; ~$3.33M cited in aggregated data). The Scientific Advisory Board is chaired by Prof. George Church of Harvard Medical School and includes Prof. Chenming Hu, inventor of the FINFET, providing dual-domain credibility across genomics and semiconductor nanotechnology.

Short descriptiontext

INanoBio is a pre-commercial biotech developing CMOS-based 3D nanopore transistor sequencing and blood-based cancer diagnostics to enable population-scale genome sequencing and pre-symptomatic disease detection for healthcare providers and research institutions.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersScottsdale, United States
HQ citystring
Scottsdale
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
nanopore DNA sequencing, cancer diagnostics, genomic sequencing platforms, precision medicine tools, biomarker detection
Industry2 codes
1Biosensors & Lab-on-Chip (BioMEMS)
CodeHDAHALAKPrimaryYes
2Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays)
CodeHLAAALALPrimaryNo
NAICS code3 codes
  • In-Vitro Diagnostic Substance Manufacturing325413
  • Analytical Laboratory Instrument Manufacturing334516
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Laboratory Analytical Instruments3826
Product category
Genomic Diagnostics
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Genome Sequencing Platform
TypeHardware Sales
Description

Revenue expected from sale of 3D nanopore transistor sequencer devices for whole human genome sequencing. The technology promises one-tenth the cost and 100x faster sequencing, positioning for population-scale genome sequencing initiatives.

inanobio.com
2Cancer Diagnostic Blood Tests
TypeOne Time License
Description

Revenue anticipated from early-stage cancer diagnostic blood tests that detect molecular biomarkers without biopsy, targeting healthcare providers and patients.

inanobio.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

INanoBio is developing advanced nano-biotechnology diagnostic platforms combining CMOS semiconductor-based 3D nanopore transistor technology, systems biology, and machine learning for high-accuracy early-stage disease detection. The company's primary offerings include a whole human genome sequencing device claimed to be 100x faster than protein nanopore sequencers at one-tenth the cost, and cancer blood test platforms that detect disease-specific molecular biomarkers without biopsy. Currently pre-commercial with technology under development and validation.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • One-tenth the cost and time of current genome sequencing
+3 more records
Product overview1 text field

INanoBio is developing a unified nano-biotechnology platform comprising three interconnected products: (1) a 3D Nanopore-Transistor Genome Sequencer — a CMOS semiconductor-based device that sequences whole human genomes with high accuracy at reduced cost and significantly faster than existing solutions; (2) a Cancer Blood Test Platform — advanced nano-biotechnology tools that detect disease-specific molecular biomarkers in blood for early cancer diagnosis without biopsy; and (3) the FENT Prototype — a fast electrochemical nanopore transistor prototype that underpins the sequencing technology. The platform integrates nanotechnology, systems biology, and machine learning to enable population-scale genome sequencing and pre-symptomatic disease detection.

Product and service4 records
13D Nanopore-Transistor Genome Sequencer
CategoryGenome Sequencing Hardware
Description

A CMOS semiconductor-based 3D nanopore-transistor device designed for whole human genome sequencing, offering high accuracy at one-tenth the current cost and time and over 100 times faster than protein nanopore-based sequencers. Targeted at healthcare providers, diagnostic laboratories, and biomedical research institutions conducting population-scale genomic studies and precision medicine programs.

2Cancer Blood Test Platform
CategoryCancer Diagnostics
Description

Advanced nano-biotechnology blood tests for early-stage cancer detection through identification of disease-specific molecular biomarkers in blood with ultra-high sensitivity. Designed to obviate the need for biopsy procedures and enable pre-symptomatic cancer diagnosis. Targeted at healthcare systems and oncologists.

3FENT (Fast Electrochemical Nanopore Transistor) Prototype
CategorySequencing Technology Prototype
Description

Novel nanopore transistor prototype developed for ultra-fast DNA sequencing applications, underpinning the company's sequencing platform speed claims. Announced in 2021 as a successful development milestone.

4Automated High-Throughput Proteomic Assay System
CategoryProteomic Assay System
Description

Advanced automated system for high throughput proteomic assays developed under NIH SBIR grant funding, supporting the company's biomarker detection capabilities for disease diagnostics.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
1Genomeweb
Strategic tierMinorTypeOthersAnnounced on2021-09-07
Description

Genomeweb provided coverage of INanoBio's FENT prototype development for fast nanopore sequencing technology, increasing industry visibility and credibility.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Market position
Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

INanoBio

Genomic Diagnosticsinanobio.com

INanoBio is a pre-commercial biotech developing CMOS-based 3D nanopore transistor sequencing and blood-based cancer diagnostics to enable population-scale genome sequencing and pre-symptomatic disease detection for healthcare providers and research institutions.

What INanoBio does

INanoBio Inc. is a private, pre-commercial biotechnology company developing nano-biotechnology platforms for early-stage disease diagnostics. Founded in 2009 and headquartered in Menlo Park, California with an additional office in Scottsdale, Arizona, the company is led by founder and CEO Bharath Takulapalli. Its stated mission is to develop high-accuracy early-stage disease diagnostics by combining CMOS semiconductor nanotechnology, systems biology, and machine learning to detect disease-specific molecular biomarkers at prodromal or pre-symptomatic stages, with the long-term vision of preemptive medicine.

The company's core technology is a CMOS semiconductor-based 3D Nanopore Transistor device intended to sequence whole human genomes with claimed high accuracy at approximately one-tenth the current cost and over 100 times the speed of protein nanopore-based sequencers. This underpins three interconnected product offerings: (1) a 3D Nanopore-Transistor Genome Sequencer for population-scale sequencing and precision medicine; (2) a Cancer Blood Test Platform that detects cancer-related biomarkers in blood with ultra-high sensitivity, intended to obviate biopsy and enable early diagnosis where stage 1 five-year survival is close to 90% versus less than 25% at stage 4; and (3) the FENT (Fast Electrochemical Nanopore Transistor) Prototype, announced in 2021 as a milestone toward ultra-fast DNA sequencing. Additional R&D streams include an Epigenetic Sequencer funded under the DARPA ECHO Program and an automated high-throughput proteomic assay system funded by an NIH SBIR grant.

INanoBio is pre-revenue and not yet commercially launched. Its go-to-market motion targets enterprise healthcare systems, diagnostic laboratories, and biomedical research institutions through direct field sales and conference-driven visibility (PMWC, MSTC, IEEE VLSI TSA). Anticipated revenue streams are hardware sales of sequencer devices and one-time licensing of cancer diagnostic blood tests, though no pricing has been publicly disclosed. To date, capital has come primarily from non-dilutive sources: a $5.4M DARPA award (2019) and a $0.7M NIH SBIR grant (2019), alongside a 2018 Series Seed round (amount undisclosed in primary sources; ~$3.33M cited in aggregated data). The Scientific Advisory Board is chaired by Prof. George Church of Harvard Medical School and includes Prof. Chenming Hu, inventor of the FINFET, providing dual-domain credibility across genomics and semiconductor nanotechnology.

INanoBio firmographics

Firmographics
Name
INanoBio
Legal name
INanoBio Inc.
Website
https://inanobio.com
Company type
Private
Founded year
2009
Operating status
Operating
Headcount range
11–50 employees
Short description
INanoBio is a pre-commercial biotech developing CMOS-based 3D nanopore transistor sequencing and blood-based cancer diagnostics to enable population-scale genome sequencing and pre-symptomatic disease detection for healthcare providers and research institutions.
Ownership category
akta.pro rank

INanoBio industry classification

Industry
Product category
Genomic Diagnostics
NAICS
In-Vitro Diagnostic Substance Manufacturing (325413), Analytical Laboratory Instrument Manufacturing (334516), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Laboratory Analytical Instruments (3826)
akta.pro primary industry
Biosensors & Lab-on-Chip (BioMEMS) (HDAHALAK)
akta.pro secondary industry
Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays) (HLAAALAL)

Keywords

  • Nanopore DNA sequencing
  • Cancer diagnostics
  • Genomic sequencing platforms
  • Precision medicine tools
  • Biomarker detection

Where INanoBio is headquartered

Location

Headquarters

HQ city
Scottsdale
HQ country
United States
HQ region
North America

Offices2 records

Markets served

INanoBio business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Infrastructure

Revenue model

  1. Genome Sequencing Platform: Revenue expected from sale of 3D nanopore transistor sequencer devices for whole human genome sequencing. The technology promises one-tenth the cost and 100x faster sequencing, positioning for population-scale genome sequencing initiatives.
  2. Cancer Diagnostic Blood Tests: Revenue anticipated from early-stage cancer diagnostic blood tests that detect molecular biomarkers without biopsy, targeting healthcare providers and patients.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels6 records

INanoBio product offering

Product offering

Core offering

INanoBio is developing advanced nano-biotechnology diagnostic platforms combining CMOS semiconductor-based 3D nanopore transistor technology, systems biology, and machine learning for high-accuracy early-stage disease detection. The company's primary offerings include a whole human genome sequencing device claimed to be 100x faster than protein nanopore sequencers at one-tenth the cost, and cancer blood test platforms that detect disease-specific molecular biomarkers without biopsy. Currently pre-commercial with technology under development and validation.

Product overview

INanoBio is developing a unified nano-biotechnology platform comprising three interconnected products: (1) a 3D Nanopore-Transistor Genome Sequencer — a CMOS semiconductor-based device that sequences whole human genomes with high accuracy at reduced cost and significantly faster than existing solutions; (2) a Cancer Blood Test Platform — advanced nano-biotechnology tools that detect disease-specific molecular biomarkers in blood for early cancer diagnosis without biopsy; and (3) the FENT Prototype — a fast electrochemical nanopore transistor prototype that underpins the sequencing technology. The platform integrates nanotechnology, systems biology, and machine learning to enable population-scale genome sequencing and pre-symptomatic disease detection.

Differentiator

Problem solved

Functional benefit

Products and services

  • 3D Nanopore-Transistor Genome Sequencer A CMOS semiconductor-based 3D nanopore-transistor device designed for whole human genome sequencing, offering high accuracy at one-tenth the current cost and time and over 100 times faster than protein nanopore-based sequencers. Targeted at healthcare providers, diagnostic laboratories, and biomedical research institutions conducting population-scale genomic studies and precision medicine programs.
  • Cancer Blood Test Platform Advanced nano-biotechnology blood tests for early-stage cancer detection through identification of disease-specific molecular biomarkers in blood with ultra-high sensitivity. Designed to obviate the need for biopsy procedures and enable pre-symptomatic cancer diagnosis. Targeted at healthcare systems and oncologists.
  • FENT (Fast Electrochemical Nanopore Transistor) Prototype Novel nanopore transistor prototype developed for ultra-fast DNA sequencing applications, underpinning the company's sequencing platform speed claims. Announced in 2021 as a successful development milestone.
  • Automated High-Throughput Proteomic Assay System Advanced automated system for high throughput proteomic assays developed under NIH SBIR grant funding, supporting the company's biomarker detection capabilities for disease diagnostics.

Quantifiable outcome

  • One-tenth the cost and time of current genome sequencing
  • +3 more outcomes

Companies that use INanoBio

Customer profile

Segments2 records

Ideal customer profiles2 records

INanoBio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

INanoBio partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • GenomewebminorOthers · 7 September 2021Genomeweb provided coverage of INanoBio's FENT prototype development for fast nanopore sequencing technology, increasing industry visibility and credibility.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

INanoBio competitors and assessment

Company assessment

Market position

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

INanoBio social profiles

Digital presence

INanoBio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

INanoBio leadership team

Management profile

Number of profiles

Profiles5 records

INanoBio funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

INanoBio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about INanoBio

What does INanoBio do?

INanoBio is developing advanced nano-biotechnology diagnostic platforms combining CMOS semiconductor-based 3D nanopore transistor technology, systems biology, and machine learning for high-accuracy early-stage disease detection. The company's primary offerings include a whole human genome sequencing device claimed to be 100x faster than protein nanopore sequencers at one-tenth the cost, and cancer blood test platforms that detect disease-specific molecular biomarkers without biopsy. Currently pre-commercial with technology under development and validation.

Is INanoBio a public or private company?

INanoBio is a private company. It is classified as venture growth investor backed and is currently operating.

When was INanoBio founded?

INanoBio was founded in 2009. It employs 11 to 50 people.

Where is INanoBio based?

INanoBio is headquartered in Scottsdale, United States, in the North America region.

How does INanoBio make money?

Two revenue lines are on record. Genome Sequencing Platform is the primary driver. The others are cancer Diagnostic Blood Tests.

Does INanoBio have an API?

No public API is recorded for INanoBio.

What industry is INanoBio in?

INanoBio's product category is Genomic Diagnostics. Its primary akta.pro industry code is HDAHALAK, Biosensors & Lab-on-Chip (BioMEMS), with a secondary code of HLAAALAL, Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays). Its NAICS code is 325413 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales